Publication on Post-Finasteride Syndrome by Dr. Ángel Cunill, Director of Andrological Clinic.
The US National Institutes of Health UU Now they also recognize Post-Finasteride Syndrome (SFP) through its Information Center on Rare and Genetic Diseases. Post-Finasteride Syndrome (PFS) is characterized by persistent sexual, neurological, and physical adverse reactions in patients who have taken finasteride. The referred symptoms include loss of libido, erectile dysfunction, depression, anxiety, panic attacks, contraction of the penis, gynecomastia, muscular atrophy, cognitive deterioration, insomnia, severely dry skin. The condition can have a severe impact on victims and their partners.
Apparently, these men can have a prolonged or permanent suppression of androgen secretion with all the side effects. It has been reported so repeatedly to the point that the FDA can no longer ignore it. There are men who have been taking Propecia for 10 years, or only some months, and end up with a disease that can be difficult to treat.
Because several studies have resulted in a significantly higher rate of high-grade prostate cancer in men who have been taking these medications (finasteride in Proscar and Propecia and dutasteride in Avodart) and the most recent concerns about Post-Finasteride Syndrome, I do not recommend it orally.
The safety of finasteride to test:
A recent study in JAMA analyzed 34 clinical trials for the treatment with finasteride of male pattern baldness (androgenic alopecia). None of the trials had an adequate safety report. “Published reports from clinical trials provide insufficient information to establish the safety profile for finasteride in the treatment of androgenic alopecia,” the authors concluded.
Studies are underway to understand the safety profile of 5-alpha reductase inhibitor drugs with respect to adverse effects and their persistence. Several studies have shown the presence of enzymes with steroidogenic capacity in the nervous system. These enzymes are able to synthesize steroids from cholesterol and metabolize the peripheral steroids that reach the nervous system through the bloodstream.
Finasteride blocks the conversion of progesterone to alopregnanolone, which is a sedative substance in the brain. Ganaloxone is a synthetic analogue of alopregnanolone, which acts as a modulator of the GABA-A system. Therefore, the use of finasteride can affect the level of GABA-A receptors in the brain. Since these drugs act on the GABA system it has a sedative effect.
Androstenediol glucuronide is a byproduct of dihydrotesterone, which is 10 times more potent than testosterone and is the best indicator that Postfinasteride Syndrome may have developed. It is produced by 5-alpha reductase, the same enzyme that blocks finasteride.
Use of finasteride in young men
The drug Finasteride is a popular therapy for male pattern baldness in young men. One study looked at 4,910 side effects in men aged 18 to 45 years taking low doses of finasteride. The researchers reported that 11.8% of those reports involved persistent sexual dysfunction and 7.9% depression.
Approximately 60% of reported cases of sexual dysfunction were tending to serious and health and regulatory agencies around the world, the medical and scientific communities are just beginning to realize the extent of the problem. The determination of the underlying biological mechanisms of this syndrome requires further clinical and basic scientific research.
There is a foundation, where you can find more information, in English: www.pfsfoundation.org